ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

APGNW Apexign Inc

0.02613
0.00 (0.00%)
Mar 27 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 0.01
Ask Price 0.0257
News -
Share Name Share Symbol Market Stock Type
Apexign Inc APGNW NASDAQ Equity Warrant
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 0.02613 19:00:00
Open Price Low Price High Price Close Price Previous Close
0.02613 0.02613
Trades Shares Traded Average Volume
0 0 -
Last Trade Type Quantity Price Currency
- 0  0.02613 USD

Apexign Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 649.64k - - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News Apexign

Date Time Source Heading
5/24/202315:35AllPennyStocks.comBiotech Soars On Acquisition Announcement
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No APGNW Message Board. Create One! See More Posts on APGNW Message Board See More Message Board Posts

APGNW Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Apexigen Inc is a clinical-stage biopharmaceutical company focusing on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. The company's pipeline of immuno-oncology therapeutic candidates is led by sotigalimab, which is in clinical development, and also includes several preclinical stage immune-oncology programs.

Your Recent History

Delayed Upgrade Clock